company background image
XLRN

Acceleron PharmaNasdaqGM:XLRN Stock Report

Market Cap

US$10.9b

7D

3.3%

1Y

57.4%

Updated

20 Nov, 2021

Data

Company Financials +
XLRN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

XLRN Stock Overview

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Rewards

Trading at 62.7% below our estimate of its fair value

Earnings are forecast to grow 63.77% per year

Risk Analysis

No risks detected for XLRN from our risk checks.

Acceleron Pharma Competitors

bluebird bio

NasdaqGS:BLUE

US$736.1m

Novartis

SWX:NOVN

CHF167.2b

Price History & Performance

Summary of all time highs, changes and price drops for Acceleron Pharma
Historical stock prices
Current Share PriceUS$178.75
52 Week HighUS$189.99
52 Week LowUS$108.82
Beta0.13
1 Month Change3.62%
3 Month Change46.35%
1 Year Change57.43%
3 Year Change252.84%
5 Year Change370.64%
Change since IPO794.20%

Recent News & Updates

Oct 04

Merger Arbitrage Mondays: Merck Acquires Acceleron For $10.8 Billion

Merck acquires Acceleron for $180 per share in cash. Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV. Five9 and Zoom Video Communications mutually terminate their merger agreement.

Shareholder Returns

XLRNUS BiotechsUS Market
7D3.3%0.4%-2.7%
1Y57.4%5.3%21.3%

Return vs Industry: XLRN exceeded the US Biotechs industry which returned 8.5% over the past year.

Return vs Market: XLRN exceeded the US Market which returned 28.1% over the past year.

Price Volatility

Is XLRN's price volatile compared to industry and market?
XLRN volatility
XLRN Average Weekly Movement4.5%
Biotechs Industry Average Movement8.6%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: XLRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: XLRN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003312Habib Dablehttps://www.acceleronpharma.com

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients.

Acceleron Pharma Fundamentals Summary

How do Acceleron Pharma's earnings and revenue compare to its market cap?
XLRN fundamental statistics
Market CapUS$10.93b
Earnings (TTM)-US$254.85m
Revenue (TTM)US$112.76m

96.9x

P/S Ratio

-42.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XLRN income statement (TTM)
RevenueUS$112.76m
Cost of RevenueUS$230.40m
Gross Profit-US$117.64m
ExpensesUS$137.22m
Earnings-US$254.85m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-4.17
Gross Margin-104.32%
Net Profit Margin-226.00%
Debt/Equity Ratio0%

How did XLRN perform over the long term?

See historical performance and comparison

Valuation

Is Acceleron Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XLRN ($178.75) is trading below our estimate of fair value ($479.84)

Significantly Below Fair Value: XLRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XLRN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: XLRN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XLRN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XLRN is overvalued based on its PB Ratio (15.2x) compared to the US Biotechs industry average (3x).


Future Growth

How is Acceleron Pharma forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

63.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XLRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: XLRN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XLRN's is expected to become profitable in the next 3 years.

Revenue vs Market: XLRN's revenue (49.2% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: XLRN's revenue (49.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XLRN is forecast to be unprofitable in 3 years.


Past Performance

How has Acceleron Pharma performed over the past 5 years?

-20.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XLRN is currently unprofitable.

Growing Profit Margin: XLRN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XLRN is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.

Accelerating Growth: Unable to compare XLRN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XLRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14%).


Return on Equity

High ROE: XLRN has a negative Return on Equity (-35.49%), as it is currently unprofitable.


Financial Health

How is Acceleron Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: XLRN's short term assets ($696.6M) exceed its short term liabilities ($57.4M).

Long Term Liabilities: XLRN's short term assets ($696.6M) exceed its long term liabilities ($12.3M).


Debt to Equity History and Analysis

Debt Level: XLRN is debt free.

Reducing Debt: XLRN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XLRN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XLRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Acceleron Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XLRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XLRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XLRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XLRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XLRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Habib Dable (52 yo)

4.92yrs

Tenure

US$5,958,427

Compensation

Mr. Habib J. Dable has been the Chief Executive Officer, President and Director at Acceleron Pharma Inc. since joining on December 1, 2016. Mr. Dable served as the President of Bayer HealthCare Pharmaceuti...


CEO Compensation Analysis

Compensation vs Market: Habib's total compensation ($USD5.96M) is below average for companies of similar size in the US market ($USD10.88M).

Compensation vs Earnings: Habib's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: XLRN's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: XLRN's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Acceleron Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Acceleron Pharma Inc.
  • Ticker: XLRN
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.932b
  • Shares outstanding: 61.16m
  • Website: https://www.acceleronpharma.com

Number of Employees


Location

  • Acceleron Pharma Inc.
  • 128 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/20 00:05
End of Day Share Price2021/11/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.